The Netherlands is among the world’s leading countries in biotechnology research, yet many promising innovations ultimately scale up abroad rather than at home. To address this challenge, seven organisations from the Delft biotech ecosystem have presented the national investment agenda Biotech op Schaal (‘Biotech at Scale’) to the Dutch Minister of Economic Affairs, Heleen Herbert.
The agenda comprises thirteen investment projects with a combined value of €335 million. Commissioned by the Ministry of Economic Affairs, the proposal was developed by dsm-firmenich, Centrient, ASR Dutch Science Park Fund, Planet B.io, Delft University of Technology, the Municipality of Delft and the Province of South Holland. More than half of the total investment will be financed by the participating organisations themselves, while support from the Dutch government is sought for the remaining amount. The ambition is to make the Netherlands a more attractive location for both the development and large-scale manufacturing of industrial biotechnology.
The investment agenda was presented on behalf of the consortium by Meindert Stolk, Deputy for the Province of South Holland. The Netherlands has the knowledge, but lacks scale-up capacity. The Netherlands excels in biotechnology research, but struggles to fully capture its economic value. Startups and innovative companies frequently encounter barriers when scaling up their technologies due to a shortage of pilot and production facilities, specialised expertise and growth capital. As a result, many innovations are commercialised abroad.
According to the consortium, this represents not only a missed economic opportunity, but also a threat to the Netherlands’ long-term earning capacity and strategic autonomy. The need for investment in industrial biotechnology is also reflected in the Dutch Government’s Biotechnology Vision 2025–2040 and the Wennink Report.
You can now read the full whitepaper at the link below


